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Use of Mediation to
Recover Rights to Our Genes
Rachel Albert*
I. INTRODUCTION
We live in an era of technology and innovation. Yet the controversial
nature of patents on genes that correlate with human disease has been
undisputed since patents were first granted.1 Scientists have made a lot of
progress since the late 1970s. They have developed new strains of plants
capable of producing higher yields and resisting viruses, as well as created
“transgenic” animals that can produce an array of human pharmaceutical
compounds.2 These compounds would otherwise be unavailable because of
the high expense of insufficient sources of supply.3 Research of genetic
materials has also allowed scientists to study the cause of human diseases
and target the specific gene sequence that creates the defect.
Patent protection attempts to strike a balance between giving both
protection and incentives that lead to inventor creation and the public
interest in preventing barriers to the flow of information that might permit
invention.4 Public controversy has centered on the contextual aspects of
diagnosing disease through the use of patents that are granted to individuals
who discovered disease-associated genes.5 However, arbitration can be

* Juris Doctor Candidate 2016, Pepperdine University School of Law.
1. Robert Cook-Deegan & Annie Niehaus, After Myriad: Genetic Testing in the Wake of
Recent Supreme Court Decisions About Gene Patents, NCBI (Sept. 11, 2014),
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225052/.
2. MARTIN ADELMAN ET AL., CASES AND MATERIALS ON PATENT LAW 67 (4th ed. 2015).
3. Id.
4. Id.
5. Two scholars have noted:
Policy reports on “gene patents” began to appear in the early mid-1990s, an indicator of
emerging policy conflict. The discovery of genetic changes associated with Huntington’s
diseases, Duchenne[,] and Becker muscular dystrophy, cystic fibrosis, neurofibromatosis,
Alzheimer’s disease and other conditions led to DNA-based diagnostic methods to
identify those at high-inherited risk in families with apparent Mendelian inheritance
patterns.
Cook-Deegan & Niehaus, supra note 1.

83

Published by Pepperdine Digital Commons, 2016

1

Pepperdine Dispute Resolution Law Journal, Vol. 16, Iss. 1 [2016], Art. 4

better utilized to solve conflicts with patented inventions. This paper will
address the way that gene patents present a special issue in arbitration.
Within the specialized body of law commonly referred to as intellectual
property (IP), federal courts are authorized to protect property that fall under
the following categories of creations of the mind: inventions, literary works,
artistic works, designs, symbols, names, and images used in commerce.6
The multiple subcategories of IP are protected with laws that govern the
legal instruments that are dedicated to each subcategory, which are patents,
copyrights, and trademarks.7 These different instruments facilitate the
inventors to earn recognition and wealth from the IP that they create.8
Therefore, it is easy to see how there needs to be a correct balance between
the credit that is due to innovators and also the interest and ability for the
public to use the inventions for the public welfare.9 Thus, the IP system
strives to allow innovation and creativity to flourish while also protecting
innovator’s rights. A specific concern of inventors is the constrained time
frame that is desired.10 If this time frame is elongated unnecessarily, then
the proceedings can be harmful to the inventor’s rights because technology
tends to evolve quickly and can render a pending invention obsolete.11
These dragged out proceedings can interfere with a business’s development
plans.12 For instance, if a company came up with a new product but is
unsure of how the patent litigation will be decided, it may be forced to end
product production until it is ultimately determined by the court Patent
licensing disputes are not typically resolved in arbitration or mediation, but
they can serve as preferable methods for resolving the patent process.
License disputes often arise when a patent owner (or licensor) licenses
gene patents to a licensee who later disputes that royalties are due because
the patent does not cover what the licensee is doing, or because the patent is
invalid.13 Recently, the Patent Office granted a substantial number of
patents on genetic sequences that may not be valid pursuant to the 2013
Supreme Court decision in Association of Molecular Pathology v. Myriad

6. What is Intellectual Property?, WIPO, http://www.wipo.int/about-ip/en/ (last visited Feb.
23, 2016).
7. Id.
8. Id.
9. Id.
10. See Craig Metcalf, Resolution of Patent and Technology Disputes by Arbitration and
Mediation: A View from the United States, 74 ARB: J. CHARTERED INST. ARBS. 385, 385 (2008),
http://www.kmclaw.com/media/article/1_metcalf-arbitration%20article.pdf.
11. Id.
12. Id.
13. See D. Brian Kacedon et al., Licensee May Challenge Patent Validity and Infringement in
Royalty Disputes When Royalties are Tied to the Practice of Licensed Patents, FINNEGAN (May 26,
2015), http://www.finnegan.com/resources/articles/articlesdetail.aspx?news=b27728c0-34d1-41629fd0-40298591522e.
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Genetics,14 which held that naturally occurring DNA segments associated
with ovarian and breast cancer claimed by Myriad were not patentable under
35 U.S.C. § 101.15 There, the Court was less than clear when it ruled that
isolated DNA in a particular sequence found in nature is not patent-eligible,
but that synthetic DNA can be patented because it is not naturally
occurring.16 Thus, patents can be granted to those who invent something
new and useful, but not for simple discovery of the location of a gene.
However, the Court did not address the patentability of DNA with
nucleotides that have been altered.17 One may wonder if patents can be
issued for sequences that have only been slightly altered.
II. SIGNIFICANCE OF THE TOPIC
By 2011, the United States Patent and Trademark Office (USPTO) had
issued over 2,500 patents claiming isolated DNA.18 In addition, the USPTO
issued 40,000 patents that were related to human genes existing in forms
other than their native form.19 Patents involving gene sequences will
undoubtedly have implications in the future involving different types of
genetic testing, agriculture, and gene therapy. For instance, if an artificial
gene can be used to treat an illness, and if the artificial gene can be patented,
it can prevent competition and make treatment more expensive for members
of the public that need it.20 Furthermore, the person who holds the patent
can hold a monopoly over the patented material and licensing fees can often
be extremely costly.21 It can also prevent further research on that specific
gene because anyone seeking to use the patented gene would need a

14. Ass’n for Molecular Pathology v. Myriad Genetics, 133 S. Ct. 2107, 2120 (2013).
15. Id. Section 101 of the Patent Act describes the subject matter that can be patented. 35
U.S.C. § 101 (2015). To be eligible to receive a utility patent, the invention must fall into one of the
four categories—processes, machines, manufactures, and compositions of matter—and must also
meet the other requirements of the Patent Act. 35 U.S.C. § 101. The Supreme Court has long held
that there are certain exceptions to this provision: laws of nature, natural phenomena, and abstract
ideas. Alice Corp. v. CLS Bank Int’l, 134 S. Ct. 2347, 2354 (2014).
16. Myriad, 134 S. Ct. at 2354. In Myriad, the Supreme Court affirmed in part and reversed in
part the decision of the Unites States Court of Appeals for the Federal Circuit. Id. at 2107.
17. Id.
18. Charles R. Macedo et al., Isolated Human Genes and Related Therapeutic Treatment
Methods Held Patent-eligible, 8 J. INTELL. PROP. L. & PRAC. 96, 96 (2013),
http://jiplp.oxfordjournals.org/content/8/2/96.abstract.
19. Id.
20. Id.
21. Sapna Kumar, Life, Liberty, and the Pursuit of Genetic Information, 65 ALA. L. REV. 625,
648 (2014).
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license.22 Even with the Myriad decision, labs may face issues where
cDNA, or synthetic DNA, is patented and they do not hold the patent.23
Complementary DNA, cDNA,24 is often used as a starting point for cloning
eukaryotic genes, and gene libraries that include only genes transcribed in a
particular tissue at a particular time can be made from complementary
DNA.25 Synthesis of cDNA is especially useful for identifying mRNAs that
are present only in a few copies.26
In some instances, even if they wish to be a licensee, they may not be
able to get a license, and if parties go to court, litigation may take years.27
Especially where health concerns can be pressing i.e. with cancer testing (the
Myriad decision), two years might make a real difference to a cancer patient
seeking to benefit from additional research on diagnostics with the BRCA
genes. Arbitration can thus be useful for its shorter time span but also can
give the added benefit of utilizing experts who actually have science
backgrounds.28 However, would an increased emphasis on arbitration harm
consumers? It may indeed harm consumers because it can keep the specific
reasons for the decision unrevealed and confidential.29 This confidentiality
would prevent other parties from quickly learning about the invalid patent
and pursuing further research, but those who do arbitrate can be rewarded in
the sense that they can reach a faster result and even get a head start on
research and development.
Also, reducing the cost of trial might reduce the cost of the patent, since
the parties involved in the arbitration dispute may factor in litigation
expenses where licensing agreements are involved. Thus, arbitration might
be a more efficient and useful solution. As an alternative to arbitration,
mediation would be feasibly utilized to diffuse a potentially hostile dispute
that could entail a harmful and longwinded litigation. Mediation could
transform this type of dispute with a more docile mode of resolution that
22. See id.
23. See Ass’n for Molecular Pathology v. Myriad Genetics, 133 S. Ct. 2107 (2013).
24. Complementary DNA is synthesized by combining an mRNA template with a 3’ poly A
tail with reverse transcriptase enzyme. A short oligo dT primer is added and allowed to hybridize
with the poly A tail. Reverse transcriptase synthesizes cDNA using the mRNA template, creating a
DNA-RNA hybrid. When synthesis is completed, the mRNA is removed, leaving single-stranded
cDNA. DNA polymerase uses the cDNA as a template to make a complementary DNA strand.
WILLIAM K. PURVES ET AL., LIFE: THE SCIENCE OF BIOLOGY 326 (7th ed. 2004).
25. Id.
26. Id.
27. Richard H. Sayler, The Case for Arbitrating Intellectual Property Licensing Disputes, 60
DISP. RESOL. J. 62, 62-65 (2005), https://www.adr.org/aaa/ShowPDF?doc=ADRSTG_012013.
28. Id.
29. See Canon VII of the AAA Code of Ethics (requiring arbitrators to maintain
confidentiality). But see Laura A. Kaster, Confidentiality in U.S. Arbitration, APPROPRIATED DISP.
RESOL.
(Spring
2012),
http://appropriatedisputesolutions.com/site/wpcontent/uploads/2013/01/Confidentiality-”DRS-NewsSpr12.pdf”.pdf.

86

https://digitalcommons.pepperdine.edu/drlj/vol16/iss1/4

4

Albert: Use of Mediation to Recover Rights to Our Genes

[Vol. 16: 83, 2016]

Use of Mediation to Recover Rights to Our Genes
PEPPERDINE DISPUTE RESOLUTION LAW JOURNAL

meets the goals of both parties and bolsters the product’s ability to serve
both the creator and the public consumer.30
III. BACKGROUND
It is likely true that, without patent protection, “the biotechnology
research that lies at the heart of these discovered [patents] might never have
occurred.”31 Some researchers also believe that “exclusive licensing of gene
patents has reduced the availability of genetic testing to patients.”32
However, due to the landmark Supreme Court decision in Myriad, many of
the previously granted gene sequence patents are now invalid.33 When the
Supreme Court makes decisions such as Myriad,34 where gene patents are
later found to be invalid, the gene patent invalidity issue can significantly
impact arbitrations involving gene patent licenses. In such cases, the
licensee can argue it is not liable to pay license fees because the gene patent
is invalid. If the arbitrator agrees, the licensee does not have to pay the
license fee. However, if the arbitration is private,35 other licensees of the
same patent will not necessarily know the result. On the other hand, if a
licensee challenges the validity of a gene patent in court, and the court finds
the patent to be invalid, this has collateral estoppel impact and releases all
licensees from payment of license fees.36 Collateral estoppel occurs when a
judgment in one court action serves as a bar in a later action to the relitigation of issues that were actually litigated and conclusively adjudicated
in the first action.37
It would be favorable for a gene patent owner to want a patent dispute to
be resolved by alternative means that allow for confidentiality so that other
30. Dispute Resolution for SMEs, WIPO ARB. & MEDIATION CTR. 1, http://www.wipo.int/
export/sites/www/sme/en/documents/pdf/arbitration_mediation.pdf (last visited Feb. 25, 2015).
31. Jennifer Vogel, Patenting DNA: Balancing the Need to Incentivize Innovation in
Biotechnology with the Need to Make High-Quality Genetic Testing Accessible to Patients, 61 U.
KAN. L. REV. 257, 292-93 (2012).
32. Kumar, supra note 21, at 648.
33. Christopher Bergin, Take Off Your Genes and Let the Doctor Have A Look: Why the Mayo
and Myriad Decisions Have Invalidated Method Claims for Genetic Diagnostic Testing, 63 AM. U.
L. REV. 173, 209 (2013).
34. Ass’n of Molecular Pathology v. Myriad Genetics, 133 S. Ct. 2107, 2120 (2013)
35. See Canon VII of the AAA Code of Ethics, which requires arbitrators to maintain
confidentiality. But see Richard C. Reuben, Confidentiality in Arbitration: Beyond the Myth, 54 U.
KAN. L. REV. 1255, 1256 (2006) (discussing the difference between confidentiality and privacy in
arbitration).
36. See Blonder-Tongue Labs. v. Univ. of Ill. Found., 402 U.S. 313 (1971).
37. See Collateral Estoppel, PRAC. L. (2016), http://us.practicallaw.com/5-518-6335.
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licensees are not aware of the outcome. Likewise, the patent challenger
often wants to avoid paying the licensing fee, but would also want to prevent
the rest of the market from violating the patent because they would not want
to draw attention to the fact that it is not a valid patent since, consequently, if
other competitors were aware, there would be more competition in the
market. Thus, both licensor and licensee may potentially favor arbitration
over litigation, and arbitration would likely make both parties to a patent
licensing dispute more content with the results instead of resorting to
litigation. Arbitration can also occur much more quickly than litigation,
allowing research to continue more quickly than if parties waited for an
outcome from litigation.38 This can have a significant impact in the medical
field, where human lives are at stake.
Patent disputes resolved through litigation cannot typically be relitigated, even if a party with an interest at stake was not initially present in
the suit.39 In Blonder-Tongue v. University of Illinois Foundation,40 the
Court set forth the rule that once a patent has been declared invalid via
judicial inquiry, a collateral estoppel barrier is created against further
litigation involving the patent, unless the patentee-plaintiff can demonstrate
that they did not have a fair chance to litigate the validity of his patent in an
earlier case.41
Despite this ruling, in Lear, Inc. v. Adkins, the Supreme Court
overturned the doctrine of licensee estoppel and held that licensees are free
to challenge the validity of a spurious patent under which they are licensed
even if a contract entered into among the parties states that he could not
challenge it, and thus, the licensee was permitted to refrain from paying
patent royalties if the patent he held a license to was deemed invalid, even if
the parties had made an agreement not to challenge its validity.42
According to the American Arbitration Association, arbitration is a tool
that is approved for the resolution for licensing and IP disputes.43
Specifically, arbitration can resolve disputes involving patents, trademarks,
and copyrights.44 In these types of disputes, arbitration has proven to be
more advantageous than litigation in terms of the following categories:
38. Barbara Kate Repa, Arbitration Pros and Cons, NOLO, http://www.nolo.com/legalencyclopedia/arbitration-pros-cons-29807.html (last visited Feb. 20, 2016).
39. See Blonder-Tongue Labs. v. Univ. of Ill. Found., 402 U.S. 313 (1971).
40. Id.
41. Id.
42. Lear, Inc. v. Adkins, 395 U.S. 653, 675-76 (1969).
43. Intellectual Property/Licensing, AM. ARB. ASS’N (2014), https://www.adr.org/aaa/faces/
aoe/commercial/intellectualpropertylicensing?_afrLoop=891677053851491&_afrWindowMode=0&
_afrWindowId=1bp2y79lfx_203#%40%3F_afrWindowId%3D1bp2y79lfx_203%26_afrLoop%3D89
1677053851491%26_afrWindowMode%3D0%26_adf.ctrl-state%3D1bp2y79lfx_227 (last visited
Feb. 20, 2016).
44. Id.
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•
•
•
•
•

speed and economy;
privacy;
reduced likelihood of damage to ongoing business relationships;
ease of enforcement in the international context; and
ability of the parties to customize the process and select arbitrators
who are experts familiar with the subject matter of the underlying
dispute.45

In order to properly facilitate arbitration in the IP law arena, the
American Arbitration Association provides panels of neutral arbitrators that
have expertise in the following areas of IP: patents, trademarks, copyrights,
This
licensing, technology, biotechnology, and pharmaceuticals.46
particularized expertise provides another great advantage over litigation,
where judges and jury-members typically have very limited scientific
knowledge.
IV. RIGHTS OF AN OWNER
The patent owner is granted the exclusive right to prevent others from
making, using, offering for sale, or selling the patented invention.47 Under
35 U.S.C. § 154 (2015), current statutory provisions, the term of protection
for utility patents is twenty years measured from the date of filing48 with
extensions of up to five years permitted for drugs, medical devices, and
additives.49 Also, under 35 U.S.C. § 173 (2015), the current term of
protection for design patents is fifteen years from the date of filing.50 The
exhaustion doctrine, which is a longstanding doctrine of patent law, entitles
a patentee to a single royalty per patented device and the rule prevents
patentees from collecting a series of royalties for a single invention.51 Thus,
the exhaustion doctrine prevents a patentee from bringing an action against a

45. Id.
46. Id.
47. See 35 U.S.C. § 154 (2015).
48. Id. § 154(a)(2).
49. Id. § 156.
50. See id. § 173.
51. Erin Julia Daida Austin, Reconciling the Patent Exhaustion and Conditional Sale
Doctrines in Light of Quanta Computer v. LG Electronics, 30 CARDOZO L. REV. 2947, 2947-49
(2009).
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third party purchaser after having already received a royalty payment from
the initial sale.52
V. PATENT ARBITRATION
The Patent Act at 35 U.S.C. § 294(a) provides that any arbitration clause
contained in a patent agreement shall be presumed valid, irrevocable, and
Also, the Supreme Court has described the Federal
enforceable.53
Arbitration Act54 as evidence of a “national policy favoring arbitration.”55
Even still, as IP attorney Chris Neumeyer explains, the number of disputes
in Patent law that undergo arbitration is small.56
Additionally,
internationally, the number is even fewer.57 In contrast, Neumeyer notes that
in 2012 the number of patent-related lawsuits increased to more than
5,000.58 These 5,000 lawsuits were all filed in U.S. District Courts. Several
well-known companies have in recent years resorted to arbitration.59 The
recent trend began in 2012 when both Research in Motion and Nokia
successfully underwent arbitration in regards to a licensing dispute.60 This
occurred in a Swedish tribunal that awarded Nokia royalties because RIM
infringed standard-essential patents (SEPs) that were owned by Nokia.61 In
2013 Google proposed that Apple use arbitration to resolve a dispute that
concerned particular patents.62 In this particular dispute, however, the
parties did not reach an agreement.63 In that same year, there was an
announcement that Tessera Technologies was owed $130 million in royalties

52. Southland Corp. v. Keating, 465 U.S. 1, 10 (1984); see Quanta Comput. v. LG Elecs., 553
U.S. 617 (2008).
53. Buckeye Check Cashing v. Cardegna, 546 U.S. 440, 443 (2006); See 35 U.S.C. § 294(a)
(2012).
54. 9 U.S.C. § 1 (2015).
55. Southland, 465 U.S. at 10; Nitro-Lift Techs. v. Howard, 133 S. Ct. 500, 501 (2012) (per
curiam).
56. Chris Neumeyer, Think Patent Arbitration Can’t Work? Think Again, IPWATCHDOG (June
10,
2013),
http://www.ipwatchdog.com/2013/06/10/think-patent-arbitration-cant-work-thinkagain/id=41447/;
see
also
About
Chris
Neumeyer,
INT’L TECH. L. BLOG,
http://techlaw.biz/author/admin/ (last visited Mar. 3, 2016).
57. Id.
58. Id.
59. See id. (discussing well-known companies such as Google, Apple, and Genetech).
60. Id.; Nokia Corp. v. Research in Motion Ltd., 2012 U.S. Dist. LEXIS 174761 (N.D. Cal.
Dec. 7, 2012)
61. Neumeyer, supra note 56.
62. Id.
63. Id.
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plus $64 million in royalties as per both a patent licensing agreement and an
order that had been previously awarded from an earlier arbitration.64
By choosing arbitration, parties are able to facilitate savings in multiple
ways. Neumeyer notes some of the following methods: to limit the amount
of arbitrators, to restrict the scope of discovery, to submit to the pleadings, to
prevent the review of a final award, and to impose limits on motions.65
Also, arbitration can provide for a significant amount of savings in patent
disputes that span across multiple jurisdictions by facilitating a single
agreement that allows the possibility of halting inter-jurisdictional
litigation.66 Arbitration also allows for flexibility, which is essential because
agreement on various logistical issues creates a smoother process. Such
logistical issues include: the location for arbitration, the qualifications of
arbitrators, access to interim relief, governing law, procedural rules,
language, evidence, and timing.67 Thus, arbitration allows parties to avoid
litigation where forums may be biased or where judges or juries are ignorant
about essential knowledge of the relevant field. To the contrary, the parties
are instilled with the power to select arbitrators who are experts, neutral, and
specialized.68 The International Chamber of Commerce has established a
working roster of professional arbitrators that hold the specialized
credentials of engineers and patent lawyers.69
There are certain situations, however, where arbitration does not provide
a resolution to patent disputes across multiple countries.70 Even still, there
are variations in the way different courts reserve the right to arbitrate
disputes. In the United States, courts can arbitrate disputes regarding patent
infringement.71 However, that is not the case in China and Japan.72 If
jurisdictions deny the ability for arbitration to govern patent disputes, then it
is highly possible that local courts may deny enforcement of awards issued
in another country.73 There are fewer grounds that are used to overturn

64. Tessera Wins Key Ruling in Arbitration Versus Amkor, TESSERA (Feb. 20, 2013),
http://ir.tessera.com/releasedetail.cfm?ReleaseID=741970.
65. Neumeyer, supra note 56.
66. Id.
67. Id.
68. Id.
69. Id.;
see
also
Arbitration
and
ADR,
INT’L
CHAMBER
OF
COM.,
http://www.iccwbo.org/advocacy-codes-and-rules/areas-of-work/arbitration-and-adr/ (last visited
Apr. 3, 2016).
70. Neumeyer, supra note 56.
71. Id.
72. Id.
73. Id.
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arbitration awards than there are court judgments.74 Typically, the main way
for arbitration to be upheld is if parties agree to the binding nature of
arbitration at any time before the arbitration occurs.75 Yet many disputes
involving patents are not derived from a pre-existing relationship.76
VI. GENE PATENTING
The human genome consists of twenty-three pairs of chromosomes
within the nucleus of all our cells, with an estimated 30,000 genes
comprising the genome.77 A genome is an organism’s makeup of DNA,
which contains the complete instructions needed to create and direct the
activities of the organism.78 DNA molecules are large polymers that encode
hereditary information that can be passed from generation to generation.79
By using an RNA intermediate, the information in DNA is used to specify
the amino acid sequence of proteins.80 DNA is made up of four nitrogenous
bases that include adenine (A), thymine (T), cytosine (C), and guanine (G).81
In double-stranded DNA, there is complementary base pairing, where A
pairs with T by forming two hydrogen bonds, and C pairs with G by forming
three hydrogen bonds.82 The nucleotide sequence of DNA is copied into
ribonucleic acid, or RNA, which is then converted in a linear sequence of
amino acids that creates a protein.83 RNA is a polynucleotide that is
different from DNA in that it contains only one strand, a different sugarribose instead of deoxyribose, and a fourth base called uracil (U) instead of
thymine.84
The two steps involving our body’s production of proteins include
transcription (which copies information of a DNA sequence into RNA) and
translation (which converts the RNA sequence into the amino acid sequence
of a polypeptide).85 Messenger RNA (mRNA) travels from the nucleus to

74. Id.
75. See United Steelworkers v. Warrior & Gulf Navigation Co., 363 U.S. 574, 582 (1960).
76. Neumeyer, supra note 56.
77. Human Genome Project Completion: Frequently Asked Questions, NAT’L HUM. GENOME
RES. INST., http://www.genome.gov/11006943 (last updated Oct. 30, 2010). On April 14, 2003, the
National Human Genome Research Institute (NHGRI), the Department of Energy (DOE) and their
partners in the International Human Genome Sequencing Consortium announced the successful
completion of the Human Genome Project. Id.
78. Id.
79. PURVES ET AL., supra note 24, at 54.
80. Id.
81. Id.
82. Id. at 218.
83. Id. at 220.
84. Id. at 236.
85. Id.
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the cytoplasm and serves as a template for the synthesis of proteins.86
Protein-coding genes contain noncoding base sequences, called introns (that
do not code for amino acids) that are interspersed with the coding regions,
called exons (that do code for amino acids).87 There are transcripts of the
introns in the primary transcript of RNA (pre-mRNA), but when the mRNA
leaves the nucleus of the cell, the introns have been removed and the exons
are spliced together.88
A much smaller DNA library, that may include only the genes
transcribed for a specific tissue, can be made from complementary DNA, or
cDNA.89 cDNA is produced by extracting mRNA from a tissue and then
allowing it to hybridize with a molecule called oligo dT (which consists of a
string of thymine residues).90 The oligo dT then serves as a primer, and by
using mRNA as a template, is able to synthesize DNA from RNA (making a
strand of cDNA that is complementary to the RNA strand, which contains
only the exons, as noted above).91 Complementary DNA is a good starting
point for the cloning of eukaryotic genes and is especially useful for cloning
genes that are expressed at low levels.92 If the amino acid sequence of a
protein is known, organic chemistry can be applied to create the DNA that
codes for the specific protein by figuring out an appropriate base sequence.93
If a mutation occurs in a nucleotide sequence, it can result in a harmless
alteration, but if it changes the amino acid that is produced, it can cause
disease.94 Because synthetic DNA can be created in any desired sequence,
DNA can also be manipulated to create specific mutations, and scientists can
then determine how the mutant DNA is expressed in the host cell.95
Scientists can also extract DNA from cells using lab methods and they are
able to isolate segments of DNA (which can be a particular gene, or part of a
gene).96 Genetic testing has led to medical breakthroughs.97

86. Id.
87. Id. at 285.
88. Id.
89. Id. at 325.
90. Id.
91. Id.
92. Id.
93. Id. at 325-26.
94. Id. at 347.
95. Id. at 326.
96. Id. at 346-48.
97. Id. For instance, it was determined that the gene responsible for fragile-X syndrome
contains a repeated triplet, CGG, at a certain point in the promoter region. Id. at 347. “[E]xpanding
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The genetic code is nearly universal, applying to all species on the
planet, with the exceptions being “few and slight.”98
Nine percent of women who inherit one mutated allele of the gene
BRCA1 have a 60% chance of having breast cancer by age fifty and an 82%
chance of developing it by age seventy.99 Women who inherit the two
normal alleles of the BRCA1 gene are 2-7%.100
Myriad found the location of the BRCA1 and BRCA2 genes where
mutations in these genes can dramatically increase the risk of breast or
ovarian cancer.101 Before its discovery, scientists did not know which genes
were associated with those cancers.102 By determining the nucleotide
sequence, Myriad was able to develop tests that are useful for detecting
mutations in these genes and assessing the risk of cancer.103 Myriad then
obtained patents after it discovered the location and sequence.104 When
Myriad determined that a lab at the University of Pennsylvania was using
similar testing methods, Myriad sent letters to the university asserting that
the testing infringed on their patents.105 GDL agreed to stop testing.106
Myriad also filed patent infringement suits against other entities that
performed BRCA testing that resulted in settlements in which defendants
agreed to cease all allegedly infringing activity.107 Years later, Ostrer, filed a
lawsuit in Myriad seeking a declaration that Myriad’s patents were invalid
under 35 U.S.C. § 101.108
Since Myriad found the genes as they occur in nature, the Court, in its
precedential decision, found that they are not patent eligible.109 However,
since a lab technician creates something new when cDNA is created, that is
a different story and the cDNA is patent eligible.110 The Supreme Court has
left it at that—that genes and the information they encode are not patent
eligible simply because they have been isolated from the surrounding
genetic material.111 The Court did not address scenarios such as if a short
triplet repeats have been found in over a dozen other diseased, such as myotonic dystrophy
(involving repeated CTG triplets) and Huntington’s disease (in which CAG is repeated).” Id.
98. Id. at 240.
99. Id. at 354.
100. Ass’n for Molecular Pathology v. Myriad Genetics, 133 S. Ct. 2107, 2120 (2013).
101. Id. at 2112.
102. Id.
103. Id. at 2112-13
104. Id. at 2113.
105. Id. at 2114.
106. Id.
107. Id.
108. Id.
109. Id. at 2117.
110. Id.
111. Id. at 2120.
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strain of DNA does not have intervening introns to be removed when the
cDNA segment is created, which would mean that it would be
indistinguishable in form from natural DNA.112
Before Myriad’s discovery of the BRCA1 and BRCA2 genes, scientists
knew that heredity played a role in establishing a woman’s risk of
developing breast and ovarian cancer, but they did not know which genes
were associated with those cancers.113 Myriad identified the exact location
of the BRCA1 and BRCA2 genes on chromosomes 17 and 13.114
Knowledge of the location of the genes allowed Myriad to determine their
nucleotide sequence.115 That information enabled Myriad to develop tests to
detect mutations in these genes.116 Before this decision was made, Myriad’s
diagnostic tools were expensive for the average uninsured consumer, costing
thousands of dollars (typically around $3,000).117 After the decision, testing
became available by other companies, and the cost of the testing decreased
and became more affordable.118 Although the decision can be looked at as
allowing more access to medical tools for the public, it can also be looked at
as giving less incentive to companies to develop new testing methods since
there appears to be less protection for those who make initial discoveries
(and less of a financial reward for these monopolistic companies).
Further, in another recent case, Ariosa Diagnostics v. Sequenom,
plaintiff Ariosa, formerly known as Aria Diagnostics, sought a declaration
that its non-invasive prenatal test, the Harmony test, using cell-free fetal
DNA circulating in the blood of a pregnant woman did not directly infringe
or contribute to the infringement of U.S. Patent No. 6,258,540 (the 540
patent), that was licensed by the defendant, Sequenom.119 Sequenom was
the exclusive licensee of the 540 patent.120 The 540 patent related to
prenatal detection methods that were “performed on a maternal serum or
plasma sample [taken] from a pregnant female,” and the methods used
detected the presence of a paternally inherited nucleic acid of fetal origin in
112. Id. at 2107-20.
113. Id. at 2112.
114. Id.
115. Id.
116. Id.
117. Maryn Wilcoxson, Note, A Lesson Learned from Myriad: The Affordable Care Act As
Both an Incentive and an Alternative for Invalidating Stem Cell Patents, 48 IND. L. REV. 723, 735
(2015).
118. Id.
119. Ariosa Diagnostics v. Sequenom, 19 F.Supp. 3d 938, 940-41 (N.D. Cal. 2013) aff’d, 788
F.3d 1371 (Fed. Cir. 2015).
120. Id. at 941.
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the sample.121 The invention was innovative because it enabled non-invasive
prenatal diagnosis, which included sex determination, blood typing, and
detection of pre-eclampsia in the mother.122 Other pre-natal diagnostic DNA
tests, such as chorionic villus sampling, utilized invasive procedures that
involved risks to the mother and the pregnancy.123 The noninvasive testing
was made possible after the discovery by two doctors that cell-free fatal
DNA (cffDNA) is detectable in maternal serum or plasma sample, and that
the detection rate was “much higher using the serum or plasma than using
the nucleated blood cell DNA extracted from a comparable volume of whole
blood.”124
Ariosa argued that the claims of the ‘540 patent were not centered on
patent eligible subject matter because the patent merely added routine and
conventional activity to a natural phenomenon.125 Yet Sequenom believed
that the methods were patentable since they were novel uses of a natural
phenomenon.126 However, in order to have a patent on a process that:
[F]ocuses upon the use of a natural law, a natural phenomenon, or
an abstract idea[,] [the invention] must contain other elements or a
combination of elements, sometimes referred to as an “inventive
concept,” sufficient to ensure that the patent in practice amounts to
significantly more than a patent 127
upon the natural law, natural
phenomenon, or abstract idea itself.
The District Court ultimately held that the only inventive concept
contained in the patent is the discovery of cffDNA, which is not
patentable.”128 Accordingly, the district court granted Ariosa’s motion for
summary judgment.129 The court believed that the effect of issuing the
patent would be to preempt all know methods of detecting cffDNA at that
time.130 The Federal Circuit later upheld the District Court’s decision.131
According to the Federal Circuit’s reasoning, the claims in that case are
method claims, which are generally eligible subject matter, yet the court
declined to rule that the claim contained an inventive concept that was
inventive enough to transform the naturally occurring phenomenon into a

121. Id.
122. Id.
123. Id. at 941.
124. Id.
125. Id. at 948.
126. Id.
127. Id. at 948-49 (citing Prometheus, 132 S.Ct. at 1294); see also Parker v. Flook, 437 U.S.
584, 594 (1978).
128. Ariosa Diagnostics v. Sequenom, Inc., 19 F.Supp. 3d 938, 950-51 (N.D. Cal. 2013) aff’d,
788 F.3d 1371 (Fed. Cir. 2015).
129. Id. at 954.
130. Id. at 949.
131. Ariosa Diagnostics v. Sequenom, Inc., 788 F.3d 1371 (Fed. Cir. 2015).
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patent-eligible invention.132 The court indicated that “patent claims should
not prevent the use of the basic building blocks of technology-abstract
ideals, naturally occurring phenomena, and natural laws.”133
Further, last year the Supreme Court decided another case regarding
patents, Alice Corp. Pty. v. CLS Bank Int’l, that was centered on patents that
disclosed a computer-implemented scheme for mitigating “settlement risk”
by using a third-party intermediary.134 The Supreme Court affirmed the
decision of the United States Court of Appeals for the Federal Circuit.135
Relying heavily on the Mayo136 decision, the court determined that the
patents were based on an abstract idea and that “the mere recitation of a
generic computer cannot transform a patent-ineligible abstract idea into a
patent-eligible invention.”137
VII. CASE LAW - COLLATERAL ESTOPPEL
In Blonder-Tongue Laboratories v. University of Illinois Foundation,
the Supreme Court held that in patent infringement suits, a patentee (a holder
of a patent) is estopped from asserting the validity of a patent that has been
declared invalid in a prior suit in federal court against a different defendant,
unless the patentee demonstrates that he did not have full and fair
opportunity, procedurally, substantively, and evidentially, to litigate the
validity of his patent in the prior suit.138 The case centered on the
patentability of antennas.139 In a prior infringement action, a patent held by
132. Id. at 1376. The court noted:
Because the claims at issue are directed to naturally occurring phenomena, we turn to the
second step of Mayo’s framework. In the second step, we examine the elements of the
claim to determine whether the claim contains an inventive concept sufficient to
“transform” the claimed naturally occurring phenomenon into a patent-eligible
application. We conclude that the practice of the method claims does not result in an
inventive concept that transforms the natural phenomenon of cffDNA into a patentable
invention.
Id. at 1376-77. See also Mayo Collaborative Servs. v. Prometheus Labs., 132 S. Ct. 1289, 1294
(2012); Parker v. Flook, 437 U.S. 584, 591 (1978) (“The process itself, not merely the mathematical
algorithm, must be new and useful.”).
133. Ariosa Diagnostics v. Sequenom, Inc., 788 F.3d 1371, 1379 (Fed. Cir. 2015).
134. Alice Corp. Pty. v. CLS Bank Int’l, 134 S.Ct. 2347, 2351 (2014).
135. Id. at 2360.
136. According to Mayo, conventional activity cannot transform an unpatentable law of nature
into patent-eligible application of such law. Mayo Collaborative Servs. v. Prometheus Labs., 132
S.Ct. 1289 (2014).
137. Alice,134 S.Ct. at 2351.
138. Blonder-Tongue Labs., v. Univ. of Ill. Found., 402 U.S. 313 (1971).
139. Id.
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the University of Illinois Foundation was determined to be invalid.140
Thereafter, the Foundation brought an action against Blonder-Tongue
Laboratories, the defendant, in the district court for alleged infringement of
the same patent.141 The District Court allowed the Foundation to bring its
infringement action against Blonder-Tongue and the Foundation
prevailed.142 The court of appeals affirmed the district court’s judgment in
favor of the Foundation.143 Blonder-Tongue then appealed to the United
States Supreme Court, arguing that non-mutual collateral estoppel precluded
the Foundation from bringing the subsequent action because the patent’s
invalidity was already established in an earlier action.144 The court held that
once a patent has been declared invalid via judicial inquiry, a collateral
estoppel barrier is created against further litigation involving the patent,
unless the patentee can establish that he did not have a fair chance to litigate
the validity of his patent in an earlier case.145
In Lear, Inc. v. Adkins, 146 an inventor brought the action against one of
the patent’s licensees for allegedly breaching the patent licensing
agreement.147 The Supreme Court ruled that there was no estoppel of the
licensee in his efforts to assert that the patent was invalid.148 Furthermore,
the Court ruled that the licensee was validly able to decline royalty payments
that had accrued if the licensee could prove the invalidity of the patent.149
The inventor responded by asserting that Lear should be forced to pay the
royalties according to the agreement, regardless of the underlying patent’s
validity.150 The Court in Lear overturned the doctrine of licensee
estoppel,151 holding that public interest considerations require that licensee
be free to challenge the validity of possibly spurious patents under which
they are licensed.152 The court held that “the equities of the licensor do not
weigh very heavily when they are balanced against the important public
interest in permitting full and free competition in the use of ideas which are
in reality a part of the public domain.”153 It reasoned that licensees may
often be the only individuals with enough economic incentive to challenge
140.
141.
142.
143.
144.
145.
146.
147.
148.
149.
150.
151.
152.
153.

Id. at 349-50.
Id. at 314.
Id. at 314-15.
Id. at 315.
Id. at 326.
Id. at 333.
Lear, Inc. v. Adkins, 395 U.S. 653 (1969).
Id.
Id.
Id.
Id. at 656.
See Automatic Radio Mfg. Co. v. Hazeltine Research, 339 U.S. 827 (1950).
Lear, 395 U.S. at 653.
Id. at 656.
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the patentability of an inventor’s discovery, and “if they are muzzled, the
public may continually be required to pay tribute to would-be
monopolists . . . .”154 The Court addressed that “the technical requirements
of contract doctrine must give way [to] the demands of the public interest in
the typical situation involving the negotiation of a license after a patent has
[been] issued.”155
In its reasoning, the Supreme Court acknowledged that a conflict exists
between the demands of contract law, forbidding a purchaser to “repudiate
his promises simply because he later becomes dissatisfied with the bargain,”
and the policy that requires “all ideas in general circulation be dedicated to
the common good unless they are protected by a valid patent.”156 Thus, the
conclusion recognizes that the equities of the licensor under contract law
were less important than the interests of the public to grant freedom in
sharing ideas and promoting competition.157 Basing its reasoning on the
strong federal policy in favor of the free use of ideas, the Court held that the
licensee, Lear, must be permitted not to pay patent royalties to Adkins if it
could prove that the patent for the gyroscope was invalid, despite the
agreement not to challenge the license.158
In contrast, typically an arbitration award cannot be used to assert
collateral estoppel in a subsequent lawsuit unless there is privity among the
parties.159 Privity requires an identity of interests, or a relationship that is
close enough to validate applying the doctrine.160 In situations where two
parties are in privity, the parties must have had their interests adequately
represented in order to be bound by such proceeding.161 Thus, if there is no
agreement to the contrary, issues decided by arbitration are able to be relitigated.162 For instance, in Vandenberg v. Superior Court, the California
Supreme Court indicated that it was “compelled to conclude that a private
arbitration award, even if judicially confirmed, can have no collateral
estoppel effect in favor of third persons . . .”163 However, there are also
154.
155.
156.
157.
158.
159.

Id. at 670.
Id. at 670-71.
Id. at 668.
Id. at 670.
Id. at 674.
See James M. Westerlind, The Preclusive Effects of Arbitration Awards, ARENT FOX (Aug.
20,
2010),
http://www.arentfox.com/sites/default/files/Mealeys-ArticlePreclusiveEffectofArbAwards.pdf.
160. Citizens for Open Access v. Seadrift Ass’n, 60 Cal. App. 4th 1053, 1070 (1998).
161. Trujillo v. County of Santa Clara, 775 F.2d 1359, 1367 (9th Cir. 1985).
162. See Vandenberg v. Superior Court, 21 Cal. 4th 815 (1999).
163. Id. at 834.
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exceptions. In Santor v. Superior Court, the First District Court of Appeals
held that since a corporation, a party in the arbitration, could act exclusively
through its agents and employees, the findings of the arbitration could be
used by third party agents/employees in establishing a basis for collateral
estoppel claims.164 The court held, “[s]ince a corporation may act only
through its agents, a finding that the corporation was liable . . . can be
pleaded by petitioners as res judicata in the subsequent action against
them.”165 The court applied the rules set forth in Bernard v. Bank of
America, and concluded that the issues decided in the arbitration proceeding
with respect to the first, second and third causes of action, were identical
with the ones that were pursued in the action against petitioners.166
Additionally, in Kelly v. Vons Cos., the court pointed out that issues
determined in arbitrations by a tribunal can be given collateral estoppel
effect when:
(1) [T]he issue is identical to that decided in the former proceeding;
(2) the issue was actually litigated and (3) necessarily decided; (4)
the doctrine is asserted against a party to the former action or one
who was in privity with such a party;
and (5) the former decision is
final and was made on the merits.167
The party can be granted collateral estoppel for that issue if the
arbitration was not an informal proceeding, but rather contained the
formality and safeguards that a formal action may have—the court there
determined that the action “had the elements of an adjudicatory
procedure.”168 Thus, in addition to the five elements listed above, to rule in
favor of applying collateral estoppel, a party needs to also establish that the
prior arbitrations had the following elements of an adjudicatory procedure:
an impartial officer, a qualified officer, a formal recording of testimony
under oath, cross-examinations, motions, discovery, and a written statement
of the decision.169 Consequently, there are exceptions to the rule to not
allow the assertion of collateral estoppel by a third party based on a prior
arbitration award, but typically collateral estoppel will not apply unless the
above listed criteria are met.170
On March 20, 2012, the United States Supreme Court ruled in Mayo
Collaborative Services v. Prometheus Laboratories171 that a process patent,

164. Sartor v. Superior Court, 136 Cal. App. 3d 322 (1982); Paloma Ramirez & Patrick
Mendes, The Use of Collateral Estoppel After Arbitration, TYSON & MENDES (Oct. 16, 2014),
http://www.tysonmendes.com/blog-collateral-estoppel/.
165. Sartor, 136 Cal. App. 3d at 328.
166. Id.
167. Kelly v. Vons Cos., 67 Cal. App. 4th 1329, 1331 (1998).
168. Id. at 1336; Ramirez & Mendes, supra note 164.
169. Ramirez & Mendes, supra note 164.
170. See Part VII, supra, and accompanying notes.
171. Mayo Collaborative Servs. v. Prometheus Labs., 132 S. Ct. 1289, 1304 (2012).
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which Prometheus Laboratories had obtained for correlations between blood
test results and patient health in determining an appropriate dosage of a
specific medication for the patient, is not eligible for a patent because the
correlation is a law of nature.172 The Court reasoned, “methods for making
such determinations were well known in the art, this step simply tells doctors
to engage in well-understood, routine, conventional activity previously
engaged in by scientists in the field.”173 The decision has been criticized for
conflating two separate patent law concepts (patent eligibility under Section
101 of the Patent Act and obviousness for patentability under Section
103),174 and potentially invalidating many patents relating to the
biotechnology, medical diagnostics and pharmaceutical industries.175
However, the American Medical Association (AMA) praised the decision
for invalidating patents that would have hampered the ability of physicians
to provide quality patient care.176
VIII. ADDITIONAL DEVELOPMENTS REGARDING PATENT DISPUTES
President Ronald Reagan was responsible for enacting laws, which were
to become 35 U.S.C. § 294 in 1983.177 This section empowered the federal
courts’ enforcement of arbitration agreements, regardless of the agreement’s
timing being prior to or following the patent disputes.178 Furthermore, the
Patent Trial and Appeal Board (PTAB) was given credibility as a judicial
power over issued patents by the America Invents Act of 2011.179 The

172. Id. at 1297 (noting a process reciting a law of nature is also not considered patentable
unless the process has features that “provide practical assurance that the process is more than a
drafting effort designed to monopolize the law of nature itself”). See also Ariosa Diagnostics v.
Sequenom, Inc., 19 F. Supp. 3d 938, 947 (N.D. Cal. 2013).
173. Mayo, 132 S. Ct. at 1291.
174. 35 U.S.C. §§ 101, 103 (2015).
175. Gene Quinn, Killing Industry: The Supreme Court Blows Mayo v. Prometheus,
IPWATCHDOG, (Mar. 20, 2012), http://www.ipwatchdog.com/2012/03/20/supreme-court-mayo-vprometheus/id=22920/.
176. Charlie Stiernberg, Supreme Court Diagnotsitc Process Claims as Unpatentable Laws of
Nature, HARV. J. L. & TECH. (Mar. 20, 2012), http://jolt.law.harvard.edu/digest/patent/mayocollaborative-servs-v-prometheus-labs-inc.
177. See Charles W. Shifley, Goodbye Patent Arbitration?, BANNERWITCOFF.COM (Fall 2014),
http://bannerwitcoff.com/_docs/library/articles/Corporate%20Counsel%20Special%20IP%20Section
.Shifley.Goodbye%20Patent%20Arbitration.pdf
178. Charles W. Shifley, Goodbye Patent Arbitration?, CORP. COUNS., (Oct.13, 2014),
http://www.corpcounsel.com/id=1202672879326/GoodbyePatentArbitration?slreturn=20150007231928.
179. Id.
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PTAB does not discern infringement issues.180 In contrast, the PTAB merely
judges the patentability of inventions.181 However, it cannot judge on claims
of patent infringement.182 Since late 2012, there have been 1,100 petitions
filed to the PTAB for the review of patents.183 Astoundingly, January
through June of 2014 saw filings increase to 125% more than the same that
were filed in 2013 as a whole.184 PTAB proceedings benefit the goals of
patent challengers because the PTAB has denied patentability to many
claims.185 Due to the recent increase in PTAB proceedings, arbitration may
have another need to be revived.
A. The Way Arbitration Works
Typically, when the disputing parties’ determination has been made to
arbitrate as opposed to litigate, the parties must give notice and agree to the
binding nature of arbitration.186 Furthermore, the resulting award of the
arbitration cannot be enforced unless the Director of the Patent Office has
been notified and this notice becomes a part of the patent’s prosecution
record.187 Notwithstanding the undeniable power of the aforementioned
agreements, the Director still maintains the ability to rule upon the nature of
invention’s patent and what it claims.188 Thus, the arbitration binds the
parties, but “the patentability of the invention goes to the public interest in
having only valid patents in existence.”189
Section 294 of the Patent Act allows for arbitration clauses in of any
contractual dispute that relates to patent validity or infringement.190 This
section usually relates to patent license agreements, but can be broader.191
Parties can agree to arbitrate either in the contract or after the dispute has
arisen.192 If they agree to arbitrate after the dispute has arisen, they may
agree to it in writing.193 Interestingly, Section 294(c) states that the award

180.
181.
182.
183.
184.
185.
186.

Id.
Id.
Id.
Id.
Id.
Id.
See David Allgeyer, Arbitrating the Patent Case Part IX: Statutory Provisions, ADR
COMMUNITY (Oct. 28, 2014), https://community.adr.org/docs/DOC-1392.
187. Id.
188. Id.
189. Id.
190. Id.; 35 U.S.C. § 294 (2012).
191. Allgeyer, supra note 186.
192. Id.
193. Id.
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binds only the parties.194 This could potentially benefit the person who holds
the patent. However, there is a lack of clarity on whether an invalidity
finding will bind the patent holder if he later sues another party to bolster
attempts to capture royalties. With arbitration, the answer is typically no, it
would not.195 However, this ambiguity stems from the fact that 294(c)
addresses that arbitration binds the parties to the dispute.196 Even though
another party will have “notice” once it is recorded, the decision of
invalidity is not binding over later disputes.197 However, a licensor can have
a provision in the arbitration clause that the award states what is owed in
royalties without giving specific reasons.198 In that case, a third party would
not be able to readily determine the rationale for the award or the invalidity
determined. Arbitration is a great alternative due to the fact that when jury
trials determine the outcome of a patent case, verdicts may seem to lack a
logical basis and jurors and judges may not understand the technology
involved or background of significant issues.199
B. Mediation
Mediation can also be “especially helpful in patent licensing and
infringement cases in which the parties can explore mergers, cross-licensing,
royalty rate negotiations, etc.”200 It makes sense to utilize mediation with
patent disputes since there can be more winners in the equation.201
Moreover, the parties agree on an outcome that “can avoid the risk of the
judge or jury giving an unreasonable award.”202 It is possible that if a patent
dispute is delayed due to litigation, a better product may be on the market
after hard earned dollars are spent and the litigation is still stagnant and
underway. Time is a crucial factor with patent licensing disputes, especially
in fields such as the pharmaceutical industry.203

194. Id.; 35 U.S.C. § 294(c) (1982).
195. Allgeyer, supra note 186.
196. Id.; See 35 U.S.C. § 294(c) (1982).
197. Allgeyer, supra note 186.
198. Sayler, supra note 27.
199. Metcalf, supra note 10, at 385.
200. Id at 386 (citing W. Levenson Dean, Let’s Make a Deal: Negotiating Resolution of
Intellectual Property Disputes Through Mandatory Mediation at the Federal Circuit, 6 JOHN
MARSHALL REV. INTELL. PROP. L. 369 (2007)).
201. Metcalf, supra note 10, at 386.
202. Id.
203. Id.
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The parties “can control how long the proceedings last and set deadlines
to ensure that no time is wasted.”204 Other notable aspects favoring
mediation is that it can induce settlement by helping to expedite the
negotiations processes earlier.205 Mediation further protects the parties’
confidentiality interests.206 Mediation uniquely enables the parties in dispute
to “customize and fortify confidentiality in order to protect trade secrets and
other valuable information.”207 Litigation’s counterpart to this flexible
confidentiality is a protective order.208 This type of order is issued in the
efforts to protect certain information from other parties.209 Parties in
mediation can make the entirety of the proceedings confidential, including
the terms of the settlement, and the communications are typically protected
and not admissible into evidence in other proceedings.210 It is clear that the
normal background of patent licensing disputes is a contract. Since the
adversarial nature of mediation is not nearly as strong as that of litigation,
the business relationship can sometimes be repaired.211 In cases that relate to
technology, the mediators are handpicked for their knowledge and
experience of the disputed field of law.212
IX. INTERNATIONAL ARBITRATION OF PATENT DISPUTES
Some of arbitration’s strong suits are that it calls for shorter
proceedings, lower costs, and knowledgeable arbitrators.213 Arbitration is
beneficial to parties in patent disputes as the parties typically choose
arbitrators that are experts with special technological or scientific expertise
in the required field.214 Because of this expert knowledge, the arbitrators can
more easily understand the nuanced subjects that become the heart of
disputes.215 Furthermore, this type of dispute resolution can help avoid
confusion and delays.216 Additionally, because arbitrators can readily
understand the pending issues, expert witnesses may not be needed and
money can further be saved.217 If an arbitrator has a depth of knowledge
204.
205.
206.
207.
208.
209.
210.
211.
212.
213.
214.
215.
216.
217.

Id.
Id.
Id.
Id.
Id.
Id.
Dean, supra note 200, at 369.
Metcalf, supra note 10, at 386.
Id.
Id. at 388.
Id.
Id.
Id.
Id.
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within the field, he will be more likely to adhere to industry standards and to
refrain from excessive punishment.218 However, with litigation, it may be
harder for members of the general public to determine the standards within
that field and how far one may have deviated from the norm. Thus, it makes
more sense for someone who knows the industry well to determine if one
has done wrong to another and what a reasonable award for the discretion
would be.219 Also, a panel of arbitrators with their combined expertise could
cover several different relevant areas to the dispute.220
Additionally, the Federal Circuit reviews patent claims from the cistrict
court under the de novo standard of review.221 This means that, once a
patent dispute reaches the Federal Circuit Court, the parties then must retry
the case from the beginning.222 Therefore, not only can litigation
exponentially increase costs of dispute resolution, but it can also allow for
confidentiality to be lost in its lengthy proceedings.223
A. International Concerns
If a patent owner has a patent that is being infringed upon in several
countries, it is imperative that the owner brings an enforcement action in all
of those countries.224 However, complications do arise in situations where
nations differ on their intellectual property philosophies.225 For instance, in
contrast to the U.S. statute, the European Patent Convention does not
explicitly state which inventions are patent eligible, but instead excludes
specific categories.226 Some countries allow patents to protect a broader

218. Id.
219. Id. at 389.
220. Id.
221. Id.
222. Id. at 390.
223. Id.
224. Id.
225. Id.
226. These categories include: “(a) discoveries, scientific theories and mathematical methods;
(b) aesthetic creations (c) schemes, rules and methods for performing mental acts, playing games or
doing business, and programs for computers; and (d) presentations of information.” Convention on
the Grant of European Patents (European Patent Convention), art. 52(2), Oct. 5, 1973 [hereinafter
EPC] (“Article 52(4) of the Convention prohibits patent protection for methods of treating the
human body, diagnostic methods practiced on humans or animals, and methods for treatment by
surgery or therapy.”); ADELMAN ET AL., supra note 2, at 67, 77-78 (“Many have interpreted the
limitation of Article 52(1) by 52(4) to embody a general policy that people using surgical,
therapeutic, or diagnostic methods as part of delivering medical treatment should not be encumbered
by patent rights.”). See, e.g., Franz-Josef Zimmer & Ulrike Langheinrich, Patentability of
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spectrum of rights, whereas some countries remain narrower in their
views.227 Consolidation several proceedings into a single proceeding is ideal
because the multi-national claims can get very complex because they can be
subject to the judgment of several jurisdictions.
International arbitration through the World Intellectual Property
Organization, also known as WIPO,228 has added benefits when utilized for
international parties.229 WIPO is a United Nations (UN) agency that
oversees treaties involving copyright, patent, and trademark laws and was
created in 1967.230 It has registered international patents and also developed
international patent legislation.231 WIPO is a self-governing body that has
drafted rules and created the Arbitration and Mediation Center to provide a
center that focuses on IP dispute resolution.232 This system offers parties an
effective alternative to international litigation.233 With 180 members, it
offers a solution when parties shy away from settling these types of disputes
in the courts of another country due to concerns over partiality.234 This
offers a somewhat simple solution when juxtaposed with the complexities
and messiness that can result in several multi-national litigants that bring
suits that are governed by various conflicting laws.235
Looking at the way ADR can be implemented reveals how, for instance,
experienced arbitrators who have a substantive background in the disputed
topics can better serve the parties at dispute than most judges could.236 In
addition, this type of experienced referee decreases expenditures and
“improves the quality of the decision” by supporting the decision with the
arbitrator’s own expertise.237 IP law’s sensitivity to timely dispute resolution
is unparalleled across multiple fields of law. Undoubtedly, there may be
exceptions to certain patent cases where litigation may be necessary.
However, many current issues surrounding patent litigation can be solved by
the use of mediation or arbitration. These modes of dispute resolution
provide parties with decisions that are better founded and more quickly
decided so that the public more readily has access to the wealth of
knowledge necessary for rapid technological innovation.
Diagnostic Methods Under the EPC: A New Referral to the Enlarged Board of Appeal by the
President of the EPO, 23 BIOTECH L. REP. 402, 405 (2004).
227. See EPC, art. 52(2).
228. WIPO, ELECTRONIC FRONTIER FOUND. (Feb. 14, 2015), https://www.eff.org/issues/wipo.
229. See id.
230. Id.; Metcalf, supra note 10, at 391.
231. Metcalf, supra note 10, at 391.
232. Id.
233. WIPO, supra note 198.
234. Metcalf, supra note 10, at 392.
235. Id.
236. Id. at 393.
237. Id.
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X. PROPOSED SOLUTION
There should be an increased use of arbitration in resolving licensing
disputes. Patent disputes, specifically those stemming from licensing
agreements, should go through arbitration because it enables parties to take
advantage of arbitration’s tendency to promote confidentiality,
specialization, finality, and cost-savings.238 Arbitration can be a voluntary
process where the parties agree to have a neutral third-party. In addition, the
disputing parties would ideally choose a highly qualified professional who
has knowledge of the nuanced field that gives rise to the dispute.239
Additionally, the informal process of arbitration offers flexibility, high pace,
and a finality that draws from arbitration’s binding nature.240 All of these
traits of arbitration support the goals of facilitating business and
innovation.241
In contrast, litigation entails an inventor filing a complaint and alleging
breach of licensing contract or infringement of patent. The defendant would
claim that the patents are invalid and therefore, there is no infringement.
This process would call for discovery and possible waiting times between
motions of past an entire year. The final judgment at trial can be continued
and delayed to a point where time has been wasted and both parties grow
stale. In addition, the opportunity for an appeal on the final verdict could
extend the case even further until the “company’s IP rights and product lines
have been in legal limbo” for years.242 If the dispute is resolved according to
arbitration rules, “[b]ecause the arbitrator understands patent law, she is able
to efficiently review and understand a large volume of testimony and
evidence, including complex technical data,”243 and can do so quickly to
potentially get a product more readily available on the market.
Other countries have even considered eliminating human gene
patents.244 Those who oppose gene patenting argue that costs of healthcare
would decrease and progress in research would increase.245 However, those
parties who support gene patenting bolster their argument with the idea that
the patent system provides the required incentives that support innovations
238. Allgeyer, supra note 186, at 10.
239. Id.
240. See Metcalf, supra note 10, at 389.
241. Allgeyer, supra note 186, at 10.
242. Id.
243. Id.
244. Kate M. Mead, Gene Patents in Australia: A Game Theory Approach, 22 PAC. RIM. L. &
POL’Y J. 751, 771 (2013).
245. Id.
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within the biotechnology field.246 Due to their profound impact on human
life and disease-prevention, gene patents present an issue that needs
modification. The complex processes of licensing and royalties can serve to
deter genetic research. Arbitration is a tool that can streamline this process
and provide better results.
XI. HOW THIS PROPOSAL COULD IMPACT PUBLIC WELFARE
On November 3, 2014, the Children’s Hospital of Eastern Ontario,
Canada brought suit against the University of Utah regarding patents held by
the university for genes associated with Long QT Syndrome.247 The
syndrome causes abnormal, life-threatening heart rhythms and children that
inherit certain genetic mutations die suddenly from the condition unless they
receive the necessary genetic testing and therapy.248 The University of Utah
first obtained Long QT gene patents in 1997, and then initially licensed its
rights to a U.S. company that did not develop any genetic testing, but did
stop other entities from studying the genes, including suing a U.S. laboratory
that was offering a Long QT test to the public.249 Due to gene patent
disputes, there was no genetic testing offered for the disorder in the United
States for two years.250 As a result, doctors could not test patients that they
believed may have the genetic mutations and, consequently, could not
prescribe the effective therapies.251 A case in point is that of 10-year old
Abigail, an American citizen, who succumbed to Long QT Syndrome and
died undiagnosed.252 Notwithstanding Myriad’s holding that a naturally
occurring genetic code cannot be patented, there are several American
universities and companies that have maintained foreign patents on the same
genes for which they hold a patent in the United States.253 PGx Health, an
American organization acting with the help of the University of Utah,
acquired licensing to Long QT.254 Through these acquired licenses, PGx
halted Canadian medical center’s efforts to administer testing to patients.255
As a result, the cost of the test skyrocketed to an unreasonably high rate of

246. Id.
247. Misha Angrist et al., Impact of Gene Patents and Licensing Practices on Access to Genetic
Testing for Long QT Syndrome, 12 GENETICS MED. 111, 154 (2010).
248. Id.
249. Id.
250. Id.
251. Sandra S. Park, The Fight to Take Back Our Genes Moves to Canada, ACLU (Nov. 6,
2014), https://www.aclu.org/blog/womens-rights/fight-take-back-our-genes-moves-canada.
252. Id.
253. Id.
254. Id.
255. Id.
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over $4,000 per patient.256 This cost was a result of international postage
rates, and is extremely unreasonable considering that local Canadian
hospitals were slated to charge a grand total of $1,500 per tested patient.257
It is clearly unethical when the corporate concern of increased income
generation takes precedence over the international availability of life-saving
testing.
A. How Could a System Be Put Into Place?
In her article, Kourtney Baltzer proposes that a clearinghouse could be
established for monitoring and enforcement of licensing deals, with a
potential alternative dispute resolution system that could include mediation
and arbitration.258 This system would be tailored to the clearinghouse’s
granted biotech patents.259 She explains how this would be attractive to
patent licensees and patent holders, because of its relative cost-effectiveness
and risk-averseness in comparison to litigation.260 Baltzer further advocates
the suggestion by specifying that the clearinghouse’s license agreements
would maintain a clause requiring that all disputes related to the license must
be resolved through the clearinghouse’s established ADR methods.261 This
system would ensure that the parties’ expectations regarding future dispute
resolution are settled on at least the forum and the methodology.262 This not
only streamlines the process but it creates a security blanket for the parties
involved, because they know the forum is fair. Systems similar to Baltzer’s
proposed alternative dispute resolution clearinghouse could have a profound
positive consequence on the future of our patents—especially since it would
prevent companies from losing years of research to litigation.
B. Discussion of Potential Objections
While it is possible that requiring arbitration and confidentiality in
licensing agreements would be harmful to consumers, it is unlikely. One

256. Id.
257. Id.
258. Kourtney Baltzer, A Clearinghouse: The Solution to Clearing Up Confusion in Gene
Patent Licensing, 24 HARV. J.L. & TECH. 519, 537 (2011).
259. Id.
260. Id.
261. Id. at 534-35.
262. Id. at 535.
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problem, however, is that arbitration clauses may be difficult to enforce. If a
clearinghouse was utilized to grant licenses, it may pose several problems.
Objections could possibly be focused on arbitration’s pitfalls. One of
these pitfalls is the limited nature of discovery under the arbitrator’s
orders.263 This limitation denies the parties the multitude of evidence that
would have otherwise been available to the parties in the pre-trial stages of
litigation.264 With the complexity that sometimes surrounds these disputes, a
lack of evidence could prove to be detrimental to a party’s claims.265
Additionally, although parties to arbitration are supposed to be bound by
their agreement to arbitrate, there is no definitive answer to the question of
how extensively the agreement can be enforced.266 For example, will the
decision be binding in future court proceeding or even those of the
USPTO?267 It is unclear where the results of litigation and the results of
arbitration intersect.
XI. CONCLUSION
Patents on genes are ready and able to disrupt innovation and
technological advancement, “as innovators may find it daunting to obtain
licenses from all of the many different patent holders of genes that can be
simultaneously screened.”268 Although Myriad269 made some headway in
preventing patents on naturally occurring genetic material, labs may still
decide not to develop a test on a disease due to licensing issues with patents,
and there is confusion stemming from that precedential decision that seemed
to cast blurred lines. The complexities that may arise from the Court’s
unclear reasoning can decrease a patient’s ability to access critical genetic
testing. Since litigation can take years, and because there are less hostile
ways of solving licensing disputes, a more widely used system of arbitration
should be put into place.270 Even though the future is unclear, it seems that
the Supreme Court will allow certain systems of DNA inventions to be
patented, though it is not likely to grant any patents for individual genes. 271
Although the innovations addressed in Myriad and Ariosa made significant

263. See Mason, Derek J., Arbitration: A Quick And Effective Means For Patent Dispute
Resolution, LICENSING EXECUTIVES SOC’Y INT’L., (Dec. 2011), http://www.oblon.com/
publications/arbitration-a-quick-and-effective-means-for-patent-dispute-resolution/.
264. Id.
265. Id.
266. Id.
267. Id.; See also Federal Arbitration Act, 9 U.S.C. §§ 1-14 (2006).
268. Baltzer, supra note 258, at 521.
269. Ass’n for Molecular Pathology v. Myriad Genetics, 133 S. Ct. 2107 (2013).
270. Cook-Deegan & Niehaus, supra note 1.
271. Id.
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contributions to the medical field, the inventions at stake were still not
patentable.272 The pivotal point of patentability will likely depend on
“methods that more clearly reflect the art of inventions rather than the labor
of discovery.”273 Perhaps the difficulties with recent Supreme Court
decisions such as Myriad hint at the fact that lines to be drawn are not so
clear. For instance, would one be able to simply make a silent mutation in
the cDNA to avoid infringing on a patent?274 Perhaps cases need to be
decided on a case-by-case basis, which seems to fit perfectly with
arbitration. Arbitration may prove to allay inventors’ fears of subjecting
their inventions to the risks of being invalidated, exposed, or negatively
publicized.275 It may also allow the licensee a quicker chance to get their
product on the market and available to those in need. Since arbitrations are
quicker, more cost-effective, and do not need to reveal specific
determinations, it may provide for the sensitivities of each party’s needs.
This allows for companies to take advantage of arbitration decisions that are
in their favor—without the need to disclose the decision to competitors, and
the patent holders do not have to face public disclosure of the decisions that
were made. Additionally, different companies may alter their invention in a
number of ways so that the arbitrators may not reach the same decision
based on the differences in their alterations. The affect of arbitration would
thereupon allow companies to make different modifications to the product,
which would be made possible by the use of arbitration. Also, the arbitrator
finds the patent is invalid and the licensee does not have to pay royalties, the
licensee would not be concerned with whether or not competitors pay
royalties. However, even if competitors do pay royalties, the previous
licensee will gain be a competitive advantage.
In conclusion, it is surprising how few arbitrations resolve disputes
related to patents.276 Internationally, the number of patent disputes that are
submitted to arbitration are merely below one thousand.277 With the benefits
of arbitration and the hazy Supreme Court decisions that implicate our
272. Ass’n for Molecular Pathology v. Myriad Genetics, 133 S. Ct. 2107, 2107 (2013); Ariosa
Diagnostics v. Sequenom, 19 F. Supp. 3d 938, 938 (N.D. Cal. 2013) aff’d, 788 F.3d 1371 (Fed. Cir.
2015).
273. Cook-Deegan & Niehaus, supra note 1.
274. See Current Events: Supreme Court Rules on Gene Patenting, HOW SCI. IS MADE (June
21, 2013), www.howscienceismade.com/2013/06/gene-patent-supreme-court.html.
275. John Conley, Myriad, Finally: Supreme Court Surprises by not Surprising, GENOMICS L.
REP. (June 2013), http://www.genomicslawreport.com/index.php/2013/06/18/myriad-finallysupreme-court-surprises-by-not-surprising/.
276. Neumeyer, supra note 56.
277. Id.
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genetic code, it seems to be an excellent means of resolution that should be
utilized more in the future. It would be wise for parties to include arbitration
agreements in their licensing agreements and would have benefits for both
parties. It is hard to predict what the future has in store and which human
diseases may be prevented. Although lines need to be more neatly
demarcated, and mediation may prove to be a special tool for solving related
disputes as they arise, it is clear that science is reaching new highs and
technology will meet new bars as it progresses. However, keeping
innovation barriers at a minimum278 is significant for an ever-evolving world
where litigation can halt progress and risk the loss of medical treatment and
the lives of those in need of care.

278. See also ADELMAN ET AL., supra note 2, at 67 (“For a time, both the case law and roll of
granted patents seemed to suggest that if you could name it, you could claim it within a patent
instrument. Accordingly, patents issues for business methods, tax strategies, computer software, and
even human genes were among controversial proprietary rights that were issued by the USPTO.”).
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